Susceptibility testing results for Streptococcus pneumoniae isolates (n ‫؍‬ 2,279) from eight European countries, examined in the PneumoWorld Study from 2001 to 2003, are presented. Overall, 24.6% of S. pneumoniae isolates were nonsusceptible to penicillin G and 28.0% were resistant to macrolides. The prevalence of resistance varied widely between European countries, with the highest rates of penicillin G and macrolide resistance reported from Spain and France. Serotype 14 was the leading serotype among penicillin G-and macrolide-resistant S. pneumoniae isolates. One strain (PW 158) showed a combination of an efflux type of resistance with a 23S rRNA mutation (A2061G, pneumococcal numbering; A2059G, Escherichia coli numbering). Six strains which showed negative results for mef(A) and erm(B) in repeated PCR assays had mutations in 23S rRNA or alterations in the L4 ribosomal protein (two strains). Fluoroquinolone resistance rates (levofloxacin MIC > 4 g/ml) were low (Austria, 0%; Belgium, 0.7%; France, 0.9%; Germany, 0.4%; Italy, 1.3%; Portugal, 1.2%; Spain, 1.0%; and Switzerland, 0%). Analysis of quinolone resistance-determining regions showed eight strains with a Ser81 alteration in gyrA; 13 of 18 strains showed a Ser79 alteration in parC. The clonal profile, as analyzed by multilocus sequence typing (MLST), showed that the 18 fluoroquinoloneresistant strains were genetically heterogeneous. Seven of the 18 strains belonged to new sequence types not hitherto described in the MLST database. Europe-wide surveillance for monitoring of the further spread of these antibiotic-resistant S. pneumoniae clones is warranted.
Streptococcus pneumoniae continues to be a significant cause of morbidity and mortality in humans (35) . The worldwide increase in the rates of antibiotic resistance in this species has become a serious problem within the last 20 years (1). Macrolide resistance in S. pneumoniae is usually caused by the presence of the erm(B) or the mefA resistance determinant. The erm(B) protein encodes a 23S rRNA methylase, and most pneumococcal strains that harbor this gene are resistant to 14-, 15-, and 16-membered-ring macrolides, lincosamides, and streptogramin B (MLS B phenotype). The mef(A) protein encodes an efflux pump that leads to resistance only to 14-and 15-membered-ring macrolides (45, 52) . Other mechanisms of macrolide resistance include changes clustered in a highly conserved region of domain V of 23S rRNA, which plays a key role in macrolide binding (6, 10, 49, 55) , and in ribosomal proteins L4 and L22. In addition, erm(TR) mutations (53) have also been described in a few clinical pneumococcal isolates (6, 10, 49, 55) .
Newer fluoroquinolones with greater potencies against S. pneumoniae licensed in Europe include levofloxacin and moxifloxacin. Because of the emergence of antimicrobial resistance in pneumococci (1) , newer fluoroquinolones are now recommended for the empirical treatment of pneumonia in adults when antimicrobial resistance is suspected (28) . Fluoroquinolones are also recommended for initial empirical therapy of selected outpatients with community-acquired respiratory tract infections (e.g., patients with acute exacerbations of chronic bronchitis) in several countries (28, 59) . Other therapeutic options (macrolides and doxycycline) are generally preferred for the treatment of uncomplicated infections in outpatients, but there is increasing concern about the misuse and overuse of fluoroquinolones, and it is believed that if abuse of this class of drugs continues unabated, we may see the demise of fluoroquinolones as useful antibiotics within the next 5 to 10 years (28) .
Pneumococcal resistance to quinolones is usually due to mutations in either parC or gyrA, or both (40) . Strains usually become fully fluoroquinolone resistant with the addition of a mutation in the other target gene (either gyrA or parC). Mutations in parE and gyrB may also contribute to resistance (37) . In addition, an efflux mechanism has been described (16) .
The PneumoWorld surveillance study was established in 2001 to study the susceptibilities of Streptococcus pneumoniae isolates from patients with noninvasive and invasive pneumococcal disease. This paper presents the results of the 2001 to 2003 PneumoWorld surveillance study of isolates submitted by 31 participating centers in eight European countries and focuses on the prevalence of macrolide and fluoroquinolone resistance geno-or phenotypes in these countries.
(This study was presented in part at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 27 Overall, 12.5% of the isolates were penicillin G intermediate (MIC ϭ 0.12 to 1 g/ml) and 12.1% were penicillin G resistant (MIC Ն 2 g/ml). However, there was considerable intercountry variation in these overall resistance rates (Table 1) .
A total of 853 pneumococcal strains showed resistance to either macrolides or penicillin G, or both (n ϭ 27), and were chosen for pneumococcal serotyping. Serotypes 14 (18.4%), 23F (13.7%), 6B (13.7%), and 19F (12.5%) were the leading serotypes among the antibiotic-resistant strains ( Table 2) . The rates of antibiotic resistance varied within countries (Table 3) .
In total, 618 pneumococcal strains showed macrolide resistance. The prevalence of macrolide resistance geno-and phenotypes varied greatly between countries. In Spain and France, where among the eight countries in this study the highest rates of macrolide resistance were reported, erm(B) was the leading genotype (Spain, 119 of 129 strains [92.3%]); France, 199 of 202 strains [98.5%]) (Table 4) . By contrast, in Germany and Austria, where relatively low rates of macrolide resistance were found, the proportion of macrolide-resistant strains with efflux was relatively high (Germany, 26 of 56 [46.2%] ; Austria, 5 of 12 [41.7%] ). In addition, in Italy a relatively high rate of mef(A)-positive strains was also observed (25.0% of all macrolideresistant strains). Six strains from Spain (n ϭ 2), Germany (n ϭ 2), Italy (n ϭ 1), and Belgium (n ϭ 1) which showed no PCR product in repeated assays for mef(A) or erm(B) were further analyzed for mutations in 23S rRNA and alterations in ribosomal proteins L4 and L22 (Table 5) . One strain from Spain (strain PW 160), which exhibited a cMLS B phenotype, showed a 23S rRNA mutation at A2060 (pneumococcal numbering; A2058 by E. coli numbering). Interestingly, this strain was ST 156 and serotype 13, indicating a serotype switch from serotype 14 to serotype 13. Two isolates, a serotype 3 strain from Eighteen strains showed resistance to fluoroquinolones (defined as a levofloxacin MIC Ն 4 g/ml). Fluoroquinolone resistance rates (mean rate, 0.8%; 18 of 2,279 pneumococcal strains) in the eight participating countries were as follows: Austria, 0% (n ϭ 160); Belgium, 0.7% (n ϭ 148); France, 0.9% (n ϭ 443); Germany, 0.4% (n ϭ 530); Italy, 1.3% (n ϭ 462); Portugal, 1.2% (n ϭ 174); Spain, 1.0% (n ϭ 310); and Swit- c Seventy-six strains (all nonmeningitis isolates) showed an MIC of 1 g/ml and were classified as cefotaxime susceptible. Of 28 isolates with an MIC of 2 g/ml, all were nonmeningitis strains and were classified as cefotaxime intermediate. Six strains exhibited an MIC of 4 g/ml and were classified as cefotaxime resistant, so that in total, 34 strains (11.0%) were cefotaxime intermediate or cefotaxime resistant.
d Two hundred seven strains showed an MIC of 1 g/ml. Of the 207 strains, 1 was a CSF isolate and was classified as cefotaxime intermediate. Of the 108 isolates with an MIC of 2 g/ml, all were nonmeningitis strains and were classified as cefotaxime intermediate. Nine strains exhibited an MIC of 4 g/ml and were classified as cefotaxime resistant, so that in total, 118 strains (5.1%) were cefotaxime intermediate or cefotaxime resistant.
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on October 14, 2017 by guest http://aac.asm.org/ zerland, 0% (n ϭ 52). The MICs and the fluoroquinolone resistance genotypes are presented in Table 6 . Sixteen of the 18 strains showed high-level ciprofloxacin resistance (MICs Ն 32 g/ml). Among the fluoroquinolones tested, clinafloxacin (MIC 90 , 0.5 g/ml; MIC range, 0.125 to 0.5 g/ml) showed the greatest potency against the levofloxacin-nonsusceptible strains. Gatifloxacin (MIC 90 , 4 g/ml; MIC range, 0.5 to 8 g/ml) and moxifloxacin (MIC 90 , 4 g/ml; MIC range, 0.25 to 4 g/ml) were also potent against levofloxacin-nonsusceptible isolates. Infections caused by fluoroquinolone-resistant pneumococci occurred more often in older patients (mean age, 66 years versus a mean age of 55.5 years for patients from whom fluoroquinolone-susceptible isolates were recovered; P ϭ 0.05).
Ten of the 18 strains additionally showed reduced sensitivity to penicillin G; and 10 strains also showed MLS B resistance (multiply resistant isolates). Nine of the strains showed additional tetracycline resistance; and five strains had a combination of fluoroquinolone, penicillin G, MLS B , and tetracycline resistance. Two clonally related strains exhibited MLS B resistance in combination with tetracycline resistance (strains PW 2304 and PW 2305) ( Table 7 . Fluoroquinolone resistance was associated with pneumococcal serogroup 19 (19A, n ϭ 5; 19F, n ϭ 2). The clonal profile of fluoroquinolone-resistant S. pneumoniae strains in Europe was heterogeneous, and only a very few clones belonged to identical sequence types (ST 66, ST 156, and a new ST, 1-5variant-6-5-6-20-1). Of note, 7 of the 18 strains belonged to new sequence types not described in the MLST database before.
Fluoroquinolone resistance has now reached some of the multiply antibiotic resistant pneumococcal clones described by the pneumococcal epidemiology network (31) Table 8) .
Analysis of a correlation of antibiotic consumption and fluoroquinolone resistance by linear regression showed that, with the exception of Belgium, all data were in the 95% confidence interval (r 2 ϭ 0.76) (Fig. 1) . These findings confirm that the consumption of fluoroquinolones may drive the development of fluoroquinolone resistance in Europe.
DISCUSSION
Large-scale surveillance programs are required to look for trends in antimicrobial resistance and are essential in the establishment of evidence-based guidelines for the treatment of infections, such as community-acquired respiratory tract infections, where pneumococci are regularly found as the key pathogen. Overall, 24.6% of the isolates of S. pneumoniae from European centers examined in the present study exhibited reduced sensitivity to penicillin G, with a generally low prevalence in countries of Central and Western Europe (Germany, 6.0%; Austria, 4.4%) and particularly high rates in France (47.6%) and Spain (61.9%). Moderate levels of resistance were found in Belgium (11.5%), Portugal (19.0%), Switzerland (17.2%), and Italy (13.0%). This intercountry variability was also found in the PROTEKT 1999 to 2000 study (12) , the Alexander Project (22, 50) , and the SENTRY Antimicrobial Surveillance Program (13, 18) . The prevalence of strains with reduced sensitivity to penicillin G in Italy and Switzerland has significantly increased compared to the prevalence in previous studies from these countries (29, 34, 60) . It remains to be seen whether this accurately represents evolution to higher rates of resistance in these countries.
Macrolides are important alternatives to ␤-lactams for the treatment of lower respiratory tract infections involving S. pneumoniae. The level of macrolide resistance in S. pneumoniae is increasing worldwide but varies widely between countries, as confirmed by the present study. In S. pneumoniae macrolide resistance rates are highest in Asian countries, such as Korea and Japan (Ͼ80%). In Europe, Italy, and France, Ͼ40% of pneumococcal isolates are reported to be macrolide resistant (12) . These large differences in resistance profiles may be explained in part by the strong association between increasing rates of macrolide usage, especially the longer-acting compounds, such as clarithromycin and azithromycin, and the development of resistance to this class of antimicrobials, as reported previously from studies in Spain and Germany (19, 46) . The importance of ribosomal mutations in the development of macrolide resistance has only recently been recognized in pneumococci (6, 9, 10). As observed in the present study, the incidence of these strains is low (6 of 2,279) in Europe. Most information available on these resistance mechanisms today is based on in vitro selection studies showing that certain structures participate in the binding of macrolides involving domains V and II of 23S rRNA (6, 9, 10) . In clinical isolates, most point mutations were identical to those found in in vitro selection studies, but new mutations were also observed. Point mutations at positions A2058, A2059, and A2062 (E. coli numbering; by pneumococcal numbering, positions A2060, A2061, and A2063) were associated with the development of macrolide resistance (27) . The A2058G and A2058U (E. coli numbering; A2060 by pneumococcal numbering) substitutions confer the highest level of MLS B resistance, with MICs of erythromycin and related macrolides of between 32 and Ͼ200 g/ml (6, 26, 27, 36, 43, 55, 58) . The relevance of some mutations in the 23S rRNA for macrolide resistance development in S. pneumoniae, such as A138G, A373T, A260G, T389C, A449C, and A1745T, as described in the present study, needs further investigation. Alterations in the L22 and L4 proteins also play an increasing role in macrolide resistance in pneumococci. (26, 43) . Fluoroquinolone-resistant S. pneumoniae strains are currently relatively rare in the eight European countries participating in the study, and the present surveillance reports resistance levels between ranging from 0% in Austria to 1.2% in Portugal. By contrast, in Hong Kong, Ireland, and some areas of Spain, fluoroquinolone resistance has reached levels of 17.8%, 15.2%, and 5%, respectively (14, 17, 21) . The newer fluoroquinolones are now recommended for the treatment of community-acquired respiratory tract infections in many European countries (59) , with a corresponding increase in drug use. In 2001, the highest levels of consumption of quinolones were observed in Portugal (4.1 defined daily doses [DDD]/ 1,000 inhabitants/day, Italy (3.8 DDD/1,000 inhabitants/day), Belgium (3.3 DDD/1,000 inhabitants/day), Spain (2.5 DDD/ 1,000 inhabitants/day), and France (2.3 DDD/1,000 inhabitants/day). Significantly lower levels of consumption were reported from Austria (1.3 DDD/1,000 inhabitants/day) and Germany (1.1 DDD/1,000 inhabitants/day) (data for Switzerland were not available). Despite generally low resistance levels, linear regression analysis showed a strong correlation between the rates of fluoroquinolone consumption and the rates of resistance (r 2 ϭ 0.76) (Fig. 1) . The clinical relevance of fluoroquinolone resistance has been proven by numerous studies (8, 42) . Clearly, the spread of fluoroquinolone resistance determinants to international clones possessing the potential for worldwide spread is worrisome, and the present study documented that fluoroquinolone resistance was associated with these international clones (Poland 6B -20, serotype 14 variant of Spain 9V -3, serotype 19F variant of Spain 23F -1, the newly described 23F variant of the (5) clones. Furthermore, 6 of the 18 fluoroquinolone-resistant strains showed multiple resistances (additional reduced sensitivity to penicillin G, MLS B resistance, and resistance to tetracycline). Therefore, further spread of these clones may be driven not only by an increase in the rate of fluoroquinolone consumption but also by an increased rate of use of ␤-lactams, macrolides, and tetracycline. In contrast to the close genetic relatedness observed in macrolide-and penicillin G-resistant pneumococcal clones throughout Europe (44), the fluoroquinolone-resistant clones observed in the present study were characterized by a relatively high genetic diversity.
In the present investigations, QRDR analysis showed that a combination of gyrA (Ser81) and parC (Ser81 and Ser79) mutations was the most widespread and responsible for high-level levofloxacin resistance. In total, 14 different alterations could be detected in gyrA (Ser81Phe, Ser81Tyr, Glu85Lys, Glu85Gly, Ser114Gly), gyrB (Gly486Glu), parC (Ser79Phe, Lys137Asn, Asp83Tyr, Asp83Gly, Ser79Tyr, Asn91Gly), and parE (Ile460Val, Asp435Asn). The parC Asp83 alteration has only recently been described among six isolates from the United States (4) and two strains from Italy (33) and may contribute to a slight increase in the levofloxacin MIC. When this alteration was seen in combination with a gyrA alteration (Ser81), the levofloxacin MIC increases to 8 g/ml (strains PW 239 and PW 836). The parC Lys137Asn alteration, which was found to be widespread among European isolates, has also been observed among multidrug-resistant S. pneumoniae isolates in the international SENTRY study (23) ; but as it was also observed among levofloxacin-susceptible strains in Korea, the effect on fluoroquinolone resistance may be low (25) . The parC Asn91Gly change has previously been found in S. pneumoniae and may be a consequence of the uptake of DNA from viridans group streptococci (3, 4) . This change was detected in one isolate that showed five alterations in the QRDR and a serotype exchange from serotype 6B to serotype 23F, underscoring the possibility that this strain may be highly competent and capable of gene exchange with other streptococci. A single or double alteration in parC leads to a lower level of levofloxacin resistance, and some strains remained levofloxacin intermediate (levofloxacin MIC ϭ 4 g/ml) but susceptible to moxifloxacin (strains PW 1443, PW 802, and PW 1601). In contrast, three strains (strains PW 603, PW 931, and PW 1026) showed high-level levofloxacin and ciprofloxacin resistance in combination with a relatively high moxifloxacin MIC, even though they had only one alteration in parC and remained the wild type for gyrA. The latter may indicate the existence of other unknown mechanisms of fluoroquinolone resistance which require further investigation. In summary, the present study showed that antibiotic resistance rates are highly variable in eight different Western European countries. Furthermore, the distribution of macrolide resistance phenotypes and genotypes varied between these countries. Presently, strains with 23S rRNA mutation or alterations in the ribosomal protein L4 do not play an important role in the spread of macrolide resistance in Western Europe. The spread of fluoroquinolone resistance to multiple-antibiotic-resistant clones is alarming, and further dissemination of these clones throughout Europe may be expected. Europe- 
